Takeda's Entyvio Demonstrates Superiority Over Adalimumab in Phase 3b Head-to-Head Trial for Ulcerative Colitis

Recently, Takeda announced that its biologic agent Entyvio (vedolizumab) demonstrated superior efficacy in a Phase 3b clinical trial. Compared with the control group receiving adalimumab, Entyvio provided greater improvement in disease status for patients with ulcerative colitis. Notably, this is the first head-to-head comparison of the efficacy of two commonly used biologics in patients with ulcerative colitis.Clinical Trial。

Ulcerative colitis, the disease targeted in this trial, is one of the most common inflammatory bowel diseases. Its hallmark symptom is recurrent inflammation in the gastrointestinal tract, which progressively worsens over time. To date, the etiology of this disease remains unclear; however, recent studies have indicated that someHeredityBoth genetic and environmental factors contribute to the pathogenesis of this disease.

In 2014, vedolizumab received approval in the United StatesFDAapproval for market launch, for the treatment of ulcerative colitis and Crohn's disease. This is a humanized monoclonal antibody targeting α4β7 integrin, which improves the condition of ulcerative colitis by blocking the binding of α4β7 integrin to MAdCAM-1 in the gut.

Following its market launch, Takeda has continued to conduct other clinical trials to explore the therapeutic potential of vedolizumab. In a Phase 3b study named VARSITYClinical TrialIn the study, researchers compared the efficacy of vedolizumab (intravenous infusion) and adalimumab (subcutaneous injection) in treating patients with moderate-to-severe ulcerative colitis. Data at 52 weeks showed that 31.3% (120/383) of patients receiving vedolizumab achieved the primary endpoint of clinical remission. In contrast, the corresponding rate in the control group was 22.5% (87/386), with a statistically significant difference between the two groups (p=0.0061).

Furthermore, vedolizumab treatment was also associated with a higher rate of mucosal healing. Specifically, the rate of mucosal healing was 39.7% in the experimental group versus 27.7% in the control group, which was also statistically significant (p=0.0005).

“The VARSITY study answered key questions regarding the selection of biologic therapies for ulcerative colitis,” said Dr. Bruce E. Sands, the study’s principal investigator. “The primary treatment goals for ulcerative colitis are clinical remission and mucosal healing. Our results highlight the benefits that vedolizumab brings to patients.”

"As the first study to compare two common biologic therapies in ulcerative colitis,"Clinical Trial“VARSITY provided invaluable insights that can help physicians make treatment choices,” said Dr. Jeff Bornstein, Executive Medical Director at Takeda. “Vedolizumab targets the α4β7 integrin, while adalimumab targets TNFα; this is also the first time we have compared the performance of two drugs with different mechanisms of action in ulcerative colitis.”Bio ValleyBioon.com）